Editas Medicine

EDIT

Editas Medicine
$27.01 -$0.43 -1.6%
BATS BZX Real Time Price as of April 24, 2019, 4:30 p.m. View Interactive EDIT Charts

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.

News & Analysis: Editas Medicine

The Fool has written over 100 articles on Editas Medicine.

All

Market Moves

Earnings

3 Top Small-Cap Stocks to Buy in April

Huami, Tanger, and Editas Medicine have small market caps, but that only leaves them more room for multibagger returns.







5 Top Gene-Editing Stocks for 2019

The future of treating disease might be gene editing, and these five stocks have the most promising technologies.





Interactive Chart